Advances in dermatology research: A comprehensive literature review

Advances in dermatology research: A comprehensive literature review

Автор: Kirolos Eskandar

Журнал: Saratov Medical Journal @sarmj

Статья в выпуске: 2 Vol.5, 2024 года.

Бесплатный доступ

In recent years, the field of dermatology has seen significant advances in our understanding of disease pathogenesis, diagnostic techniques, and therapeutic interventions. The objective of this literature review is to provide an overview of ten key subtopics in contemporary dermatology research. First, I examined cutting-edge developments in skin cancer detection and treatment, acne and psoriasis management strategies, and the evolving therapeutic landscape for atopic dermatitis. Additionally, we delve into the clinical significance of skin manifestations associated with systemic diseases and analyze emerging trends in cosmetic dermatology. Further on, we discuss innovations in wound healing, diagnosis and treatment of hair disorders, and dermatological conditions unique to pediatric patients. Finally, we explore the role of telemedicine in dermatology practice, highlighting its potential to revolutionize patient care and access to specialty services. Through a synthesis of the current literature, this review offers insight into forefront dermatology research and emphasizes the importance of continued innovation to improve patient outcomes and quality of care.

Еще

Dermatology, skin cancer, therapeutics, telemedicine, pediatric dermatology

Короткий адрес: https://sciup.org/149147112

IDR: 149147112   |   DOI: 10.15275/sarmj.2024.0202

Список литературы Advances in dermatology research: A comprehensive literature review

  • Zaheri S, Ali I. Recent Advances in Dermatology. JP Medical Ltd., 2019.
  • Dildar M, Akram S, Irfan M, et al. Skin cancer detection: A review using deep learning techniques. International Journal of Environmental Research and Public Health 2021; 18(10): 5479. https://doi.org/10.3390/ijerph18105479
  • Lee HJ, Kim M. Challenges and future trends in the treatment of psoriasis. International Journal of Molecular Sciences 2023; 24(17): 13313. https://doi.org/10.3390/ijms241713313
  • Pescitelli L, Rosi E, Ricceri F, et al. Novel therapeutic approaches and targets for the treatment of atopic dermatitis. Current Pharmaceutical Biotechnology 2021; 22(1): 73–84. https://doi.org/10.2174/1389201021666200611112755
  • Quddusi FI, Youssef MJ, Davis DMR. Dermatologic manifestations of systemic diseases in childhood. Pediatrics in Review 2021; 42(12): 655–671. https://doi.org/10.1542/pir.2020-000679
  • Sivesind TE, Szeto MD, Kim W, Dellavalle RP. Google trends in dermatology: Scoping review of the literature. JMIR Dermatology 2021; 4(1): e27712. https://doi.org/10.2196/27712
  • Deng X, Gould M, Ali MA. A review of current advances for wound healing: Biomaterial applications and medical devices. Journal of Biomedical Materials Research. Part B, Applied Biomaterials 2022; 110(11): 2542–2573. https://doi.org/10.1002/jbm.b.35086
  • Wolff H, Fischer TW, Blume-Peytavi U. The diagnosis and treatment of hair and scalp diseases. Deutsches Arzteblatt International 2016; 113(21): 377–386. https://doi.org/10.3238/arztebl.2016.0377
  • Gilliam AE. Future directions in pediatric dermatology. Pediatric Annals 2005; 34(3), 240–242. https://doi.org/10.3928/0090-4481-20050301-12
  • Trettel A, Eissing L, Augustin M. Telemedicine in dermatology: Findings and experiences worldwide – A systematic literature review. Journal of the European Academy of Dermatology and Venereology: JEADV 2018; 32(2): 215–224. https://doi.org/10.1111/jdv.14341
  • Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians 2018; 68(6): 394–424. https://doi.org/10.3322/caac.21492
  • Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. The Lancet. Oncology 2002; 3(3): 159–165. https://doi.org/10.1016/s1470-2045(02)00679-4
  • Tschandl P, Rinner C, Apalla Z, et al. Human–computer collaboration for skin cancer recognition. Nature Medicine 2020; 26(8), 1229–1234. https://doi.org/10.1038/s41591-020-0942-0.
  • Cristescu MI, Popa LG, Cozma EC, et al. The Importance of in vivo reflectance confocal microscopy in a case of desmoplastic melanoma. Life 2024; 14(5):574. https://doi.org/10.3390/life14050574
  • Mayes PA, Hance KW, Hoos A. The promise and challenges of immune agonist antibody development in cancer. Nature Reviews. Drug Discovery 2018; 17(7): 509–527. https://doi.org/10.1038/nrd.2018.75
  • Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2015; 33(25): 2780–2788. https://doi.org/10.1200/JCO.2014.58.3377
  • Cohen DK, Goldberg DJ. Mohs micrographic surgery: Past, present, and future. Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery 2019; 45(3): 329–339. https://doi.org/10.1097/DSS.0000000000001701
  • Chia HY, Koh SL, Theng TS, Chong WS. Topical photodynamic therapy in the treatment of basal cell carcinoma in Singaporean Chinese patients. Indian Journal of Dermatology, Venereology and Leprology 2015; 81(2): 151–154. https://doi.org/10.4103/0378-6323.152180
  • Robert C, Schachter J, Long GV, et al. KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. The New England Journal of Medicine 2015; 372(26): 2521–2532. https://doi.org/10.1056/NEJMoa1503093
  • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews. Cancer 2012; 12(4): 252–264. https://doi.org/10.1038/nrc3239
  • Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. The New England Journal of Medicine 2015; 373(1): 23–34. https://doi.org/10.1056/NEJMoa1504030
  • Slominski RM, Kim T-K, Janjetovic Z, et al. Malignant melanoma: An overview, new perspectives, and vitamin D signaling. Cancers 2024; 16(12): 2262. https://doi.org/10.3390/cancers16122262
  • Brożyna AA, Hoffman RM, Slominski AT. Relevance of vitamin D in melanoma development, progression and therapy. Anticancer Research 2020; 40(1): 473–489. https://doi.org/10.21873/anticanres.13976
  • Slominski AT, Brożyna AA, Kim TK, et L. CYP11A1 derived vitamin D hydroxyderivatives as candidates for therapy of basal and squamous cell carcinomas. International Journal of Oncology 2022; 61(2), 96. https://doi.org/10.3892/ijo.2022.5386
  • Slominski AT, Kim TK, Janjetovic Z, et al. Biological effects of CYP11A1-derived vitamin D and lumisterol metabolites in the skin. Journal of Investigative Dermatology 2024. https://doi.org/10.1016/j.jid.2024.04.022
  • Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocrine Reviews 2000; 21(5): 457–487. https://doi.org/10.1210/edrv.21.5.0410
  • Anderson ZT, Dawson AD, Slominski AT, Harris ML. Current insights into the role of neuropeptide Y in skin physiology and pathology. Frontiers in Endocrinology 2022; 13: 838434. https://doi.org/10.3389/fendo.2022.838434
  • Slominski AT, Slominski RM, Raman C, et al. Neuroendocrine signaling in the skin with a special focus on the epidermal neuropeptides. American Journal of Physiology. Cell Physiology 2022; 323(6): C1757–C1776. https://doi.org/10.1152/ajpcell.00147.2022
  • Smith SM, Vale WW. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues in Clinical Neuroscience 2006; 8(4): 383–395. https://doi.org/10.31887/DCNS.2006.8.4/ssmith
  • Slominski AT, Zmijewski MA, Plonka PM, et al. How UV light touches the brain and endocrine system through skin, and why. Endocrinology 2018; 159(5): 1992–2007. https://doi.org/10.1210/en.2017-03230
  • Slominski RM, Chen JY, Raman C, Slominski AT. Photo-neuro-immuno-endocrinology: How the ultraviolet radiation regulates the body, brain, and immune system. Proceedings of the National Academy of Sciences 2024; 121(14). https://doi.org/10.1073/pnas.2308374121
  • Chen Y, Lyga J. Brain-skin connection: Stress, inflammation and skin aging. Inflammation & Allergy Drug Targets 2014; 13(3): 177–190. https://doi.org/10.2174/1871528113666140522104422
  • Furue K, ItoT, Tsuji G, et al. Psoriasis and the TNF/IL23/IL17 axis. Giornale italiano di Dermatologia e Venereologia : Organo Ufficiale, Societa Italiana di Dermatologia e Sifilografia 2019; 154(4): 418–424. https://doi.org/10.23736/S0392-0488.18.06202-8
  • Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. The Journal of Allergy and Clinical Immunology 2017; 140(3): 645–653. https://doi.org/10.1016/j.jaci.2017.07.004
  • Gholami A, Vafaeian A, Daneshpazhooh M, et al. Treatment resistance to TNF-α inhibitors in patients with psoriasis. Dermatologic Therapy 2023 (1). https://doi.org/10.1155/2023/7399468
  • Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. Journal of the American Academy of Dermatology 2008; 58(1): 106–115. https://doi.org/10.1016/j.jaad.2007.09.010
  • Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase II dose-ranging study. The British Journal of Dermatology 2013;168(2): 412–421. https://doi.org/10.1111/bjd.12110
  • Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials. Lancet 2015; 386(9993): 541–551. https://doi.org/10.1016/S0140-6736(15)60125-8
  • Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: A Phase 2b randomized placebo-controlled dose-ranging study. The British Journal of Dermatology 2012; 167(3): 668–677. https://doi.org/10.1111/j.1365-2133.2012.11168.x
  • Malara G, Politi C, Trifirò C, ey al. Effectiveness of Apremilast in Real Life in Patients with Psoriasis: A Longitudinal Study. Acta dermato-venereologica 2021; 101(9): adv00545. https://doi.org/10.2340/00015555-3846
  • Girolomoni G, Strohal R, Puig L, et al. The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology: JEADV 2017; 31(10): 1616–1626. https://doi.org/10.1111/jdv.14433
  • Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. The Journal of Allergy and Clinical Immunology 2017; 140(3): 645–653. https://doi.org/10.1016/j.jaci.2017.07.004s
  • Li SJ, Perez-Chada LM, Merola JF. TNF inhibitor-induced psoriasis: Proposed algorithm for treatment and management. Journal of Psoriasis and Psoriatic Arthritis 2019; 4(2): 70–80. https://doi.org/10.1177/2475530318810851
  • Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: A Phase 2b randomized placebo-controlled dose-ranging study. The British Journal of Dermatology 2012; 167(3): 668–677. https://doi.org/10.1111/j.1365-2133.2012.11168.x
  • Gisondi P, Girolomoni G. Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis. Drug design, development and therapy 2016; 10: 1763–1770. https://doi.org/10.2147/DDDT.S108115
  • Guttman-Yassky E, Waldman A, Ahluwalia J, et al. Atopic dermatitis: Pathogenesis. Seminars in Cutaneous Medicine and Surgery 2017; 36(3): 100–103. https://doi.org/10.12788/j.sder.2017.036
  • Weidinger S, O’Sullivan M, Illig T, et al. Filaggrin mutations, atopic eczema, hay fever, and asthma in children. Journal of Allergy and Clinical Immunology 2008; 121(5): 1203-1209.e1. https://doi.org/10.1016/j.jaci.2008.02.014
  • Weidinger S, Novak N. Atopic dermatitis. Lancet 2016; 387(10023): 1109–1122. https://doi.org/10.1016/S0140-6736(15)00149-X
  • Simpson EL, Kircik L, Blauvelt A, et al. Ruxolitinib cream in adolescents/adults with atopic dermatitis meeting severity thresholds for systemic therapy: Exploratory analysis of pooled results from two Phase 3 studies. Dermatology and Therapy 2024; https://doi.org/10.1007/s13555-024-01219-8
  • Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. Journal of the American Academy of Dermatology 2021; 85(4): 863–872. https://doi.org/10.1016/j.jaad.2021.04.085
  • Simpson EL, Thyssen JP, Silverberg JI, et al. Ruxolitinib cream for the treatment of atopic dermatitis: A phase 3 randomized trial. Lancet 2021; 398(10301): 2331-2341.
  • Kantor R, Silverberg JI. Environmental risk factors and their role in the management of atopic dermatitis. Expert Review of Clinical Immunology 2017; 13(1): 15–26. https://doi.org/10.1080/1744666X.2016.1212660
  • Sidbury R, Davis DM, Cohen DE, et al. American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents. Journal of the American Academy of Dermatology 2014; 71(2): 327–349. https://doi.org/10.1016/j.jaad.2014.03.030
  • Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 trials of dupilumab versus placebo in atopic dermatitis. The New England Journal of Medicine 2016; 375(24): 2335–2348. https://doi.org/10.1056/NEJMoa1610020
  • Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. The New England Journal of Medicine 2014; 371(2): 130–139. https://doi.org/10.1056/NEJMoa1314768
  • Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: A randomized clinical trial. JAMA Dermatology 2020; 156(12): 1333–1343. https://doi.org/10.1001/jamadermatol.2020.3260
  • McDowell L, Olin B. Crisaborole: A novel nonsteroidal topical treatment for atopic dermatitis. The Journal of Pharmacy Technology: JPT: official publication of the Association of Pharmacy Technicians 2019; 35(4): 172–178. https://doi.org/10.1177/8755122519844507
  • Bolognia JL, Schaffer JV, Cerroni L, Callen JP. Dermatology 2018.
  • Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis and rheumatism 1997; 40(9): 1725. https://doi.org/10.1002/art.1780400928
  • Kuhn A, Wozniacka A, Szepietowski JC, et al. Photoprovocation in cutaneous lupus erythematosus: A multicenter study evaluating a standardized protocol. The Journal of Investigative Dermatology 2011; 131(8): 1622–1630. https://doi.org/10.1038/jid.2011.101
  • Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmunity Reviews 2005; 4(5): 253–263. https://doi.org/10.1016/j.autrev.2004.10.003
  • Murphy-Chutorian B, Han G, Cohen SR. Dermatologic manifestations of diabetes mellitus: A review. Endocrinology and Metabolism Clinics of North America 2013; 42(4): 869–898. https://doi.org/10.1016/j.ecl.2013.07.004
  • Duff M, Demidova O, Blackburn S, Shubrook J. Cutaneous manifestations of diabetes mellitus. Clinical Diabetes: A publication of the American Diabetes Association 2015; 33(1): 40–48. https://doi.org/10.2337/diaclin.33.1.40
  • Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. The New England Journal of Medicine 1991; 325(21): 1487–1498. https://doi.org/10.1056/NEJM199111213252107
  • Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). Journal of the European Academy of Dermatology and Venereology: JEADV 2020; 34(9): 1900–1913. https://doi.org/10.1111/jdv.16752
  • Werth VP, Askanase AD, Lundberg IE. Importance of collaboration of dermatology and rheumatology to advance the field for lupus and dermatomyositis. International Journal of Women’s Dermatology 2021; 7(5Part A): 583–587. https://doi.org/10.1016/j.ijwd.2021.09.002
  • Leal JM, de Souza GH, Marsillac PF, Gripp AC. Skin manifestations associated with systemic diseases - Part II. Anais Brasileiros de Dermatologia 2021; 96(6): 672–687. https://doi.org/10.1016/j.abd.2021.06.003
  • Carruthers A, Kane MA, Flynn TC, et al. The convergence of medicine and neurotoxins: A focus on botulinum toxin type A and its application in aesthetic medicine--a global, evidence-based botulinum toxin consensus education initiative: Part I: Botulinum toxin in clinical and cosmetic practice. Dermatologic Surgery: official publication for American Society for Dermatologic Surgery 2013; 39(3 Pt 2): 493–509. https://doi.org/10.1111/dsu.12147
  • Hou A, Cohen B, Haimovic A, Elbuluk N. Microneedling: A comprehensive review. Dermatologic Surgery: official publication for American Society for Dermatologic Surgery 2017; 43(3): 321–339. https://doi.org/10.1097/DSS.0000000000000924
  • Benar H, Benar EB. A new nonsurgical combination approach for skin tightening and remodeling; Endoskin—A comparative study. Journal of Cosmetic Dermatology 2024. https://doi.org/10.1111/jocd.16306
  • O'Connor AA, Lowe PM, Shumack S, Lim AC. Chemical peels: A review of current practice. The Australasian Journal of Dermatology 2018; 59(3): 171–181. https://doi.org/10.1111/ajd.12715
  • Karimipour DJ, Karimipour G, Orringer JS. Microdermabrasion: An evidence-based review. Plastic and Reconstructive Surgery 2010; 125(1): 372–377. https://doi.org/10.1097/PRS.0b013e3181c2a583
  • Carruthers A, Sadick N, Brandt F, et al. Evolution of facial aesthetic treatment over five or more years: A retrospective cross-sectional analysis of continuous onabotulinumtoxinA treatment. Dermatologic Surgery: official publication for American Society for Dermatologic Surgery 2015; 41(6): 693–701. https://doi.org/10.1097/DSS.0000000000000340
  • Machado RA, Oliveira LQ, Martelli-Júnior H, et al. Adverse reactions to the injection of face and neck aesthetic filling materials: A systematic review. Medicina Oral, Patologia Oral y Cirugia Bucal 2023; 28(3): e278–e284. https://doi.org/10.4317/medoral.25713
  • Husein-ElAhmed H, Steinhoff M. Laser and light-based therapies in the management of rosacea: An updated systematic review. Lasers in Medical Science 2021; 36(6): 1151–1160. https://doi.org/10.1007/s10103-020-03200-1
  • Boateng J, Catanzano O. Advanced therapeutic dressings for effective wound healing--A review. Journal of Pharmaceutical Sciences 2015; 104(11): 3653–3680. https://doi.org/10.1002/jps.24610
  • Hermans MH. Silver-containing dressings and the need for evidence. The American Journal of Nursing 2006; 106(12): 60–69. https://doi.org/10.1097/00000446-200612000-00025
  • Barrientos S, Stojadinovic O, Golinko MS, et al. Growth factors and cytokines in wound healing. Wound Repair and Regeneration: official publication of the Wound Healing Society [and] the European Tissue Repair Society 2008; 16(5): 585–601. https://doi.org/10.1111/j.1524-475X.2008.00410.x
  • Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, et al. Autologous platelet-rich plasma for treating chronic wounds. The Cochrane Database of Systematic Reviews 2016(5); CD006899. https://doi.org/10.1002/14651858.CD006899.pub3
  • Murphy SV, Atala A. 3D bioprinting of tissues and organs. Nature Biotechnology 2014; 32(8): 773–785. https://doi.org/10.1038/nbt.2958
  • Kim JY, Suh W. Stem cell therapy for dermal wound healing. International Journal of Stem Cells 2010; 3(1): 29–31. https://doi.org/10.15283/ijsc.2010.3.1.29
  • Apelqvist J. Diagnostics and treatment of the diabetic foot. Endocrine 2012; 41(3): 384–397. https://doi.org/10.1007/s12020-012-9619-x
  • Sharma R, Sharma SK, Mudgal SK, et al. Efficacy of hyperbaric oxygen therapy for diabetic foot ulcer, a systematic review and meta-analysis of controlled clinical trials. Scientific Reports 2021; 11(1): 2189. https://doi.org/10.1038/s41598-021-81886-1
  • Guo S, Dipietro LA. Factors affecting wound healing. Journal of Dental Research 2010; 89(3): 219–229. https://doi.org/10.1177/0022034509359125
  • Ojeh N, Pastar I, Tomic-Canic M, Stojadinovic O. Stem cells in skin regeneration, wound healing, and their clinical applications. International Journal of Molecular Sciences 2015; 16(10): 25476-25501. https://doi.org/10.3390/ijms161025476
  • Drakos A, Vender R, Torres T. Topical roflumilast for the treatment of psoriasis. Expert Review of Clinical Immunology 2023; 19(9): 1053–1062. https://doi.org/10.1080/1744666X.2023.2219897
  • Eichenfield LF, Simpson EL, Papp K, et al. Efficacy, safety, and long-term disease control of ruxolitinib cream among adolescents with atopic dermatitis: Pooled results from two randomized Phase 3 studies. Am J Clin Dermatol. 2024; 25: 669–683. https://doi.org/10.1007/s40257-024-00855-2
  • Brownstone N. Psoriasis therapies in 2024 and beyond. Dermatology Times 2024. URL: https://www.dermatolog ytimes.com/view/psoriasis-therapies-in-2024-and-beyond
  • Gold LS, Adam DN, Albrecht L, et al. Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial. Journal of the American Academy of Dermatology 2024; https://doi.org/10.1016/j.jaad.2024.03.030
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp